Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 26, 2024 04:13 ET | Source: Research and Markets

Cancer Immunotherapy Market Research Report 2025-2029: Curing Cancer is Generating Enormous New Markets - How Big Are They? Where is the Opportunity?

Dublin, Dec. 26, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant...
December 16, 2024 16:01 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
December 12, 2024 16:51 ET | Source: Candel Therapeutics

Candel Therapeutics Announces $80 Million Proposed Public Offering

NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
December 11, 2024 06:00 ET | Source: Enterome

Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite...
December 10, 2024 11:43 ET | Source: Enterome

Enterome’s Immunotherapy EO2463 Shows Early Clinical Response in Newly Diagnosed Follicular Lymphoma Suggesting a Potential Alternative to 'Watchful Waiting'

46% objective response rate, with 15% complete responses and 31% partial responses in patients with early-stage follicular lymphoma reported at the ASH 2024 meeting.Well-tolerated treatment with no...
December 05, 2024 10:16 ET | Source: Research and Markets

Immuno-Oncology Strategic Industry Research Report 2023-2024 & 2030: Approval of Pembrolizumab (Keytruda) and Nivolumab (Opdivo), which Target PD-1 and PD-L1 Pathways have Set New Benchmarks

Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immuno-Oncology...
November 14, 2024 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

On track for topline disease-free survival data from the phase 3 randomized controlled clinical trial of CAN-2409 in localized intermediate/high risk prostate cancer, expected in Q4 2024On track for...
November 06, 2024 06:00 ET | Source: Enterome

Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting

Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting initial data from Cohort 2 as monotherapy in a...
October 24, 2024 10:14 ET | Source: Research and Markets

CD40 Agonists & CD40/Ligand Antagonists Pipeline Market Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "CD40 Agonists & CD40/L Antagonists Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...
September 19, 2024 09:41 ET | Source: Research and Markets

Groundbreaking Market Report Forecasts Significant Growth in Cancer Immunotherapy by 2027

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...